Although median survival is longer for Hispanic and black patients compared with white patients, health-related QoL is poor for minority patients.
Decreased liver tumor growth and improved survival in a mouse model were noted after injecting iPS-ML/IFN-β.
Exercise helps patients with gastrointestinal cancer undergoing chemotherapy cope with their disease and treatment.
ACS colorectal cancer statistics show an overall decrease in incidence due to increases in screening rates; however, age-related incidence is trending up in younger persons, down in older persons.
A phase 3 analysis of SWOG Intergroup Trial S0033 reveals that imatinib significantly extends survival in patients with GIST.
Outcomes improved with short-course radiation and delay to surgery of 4 to 8 weeks.
Women with poor metabolic health have a greater risk of colorectal cancer than those with increased weight.
Clinical trials show pembrolizumab active against mucosal melanoma, extends survival in bladder cancer.
An investigation into whether onset or worsening of diabetes causes pancreatic cancer or vice versa was presented at the 2017 European Cancer Congress.
Research presented at the 2017 European Cancer Congress describes the potential of a noninvasive diagnostic test for esophageal and gastric cancers that measures chemicals in the breath.
Chemotherapy may be overused among young and middle-aged adults with colon cancer, with the addition of adjuvant chemotherapy not resulting in a matched survival benefit.
PDX1 appears to have distinct roles at different stages of pancreatic cancer development.
Researchers conduct a retrospective cohort study of histologically diagnosed gastrointestinal stromal tumors in the Surveillance, Epidemiology, and End Results (SEER) database.
Researchers have found that hepatitis C virus infection is associated with an elevated risk for developing bile duct cancers and diffuse large B-cell lymphoma.
In a phase 3 trial, researchers determined if weekly nab-paclitaxel was noninferior to weekly solvent-based paclitaxel with respect to overall survival in patients requiring second-line treatment for advanced gastric cancer.
Findings are presented from an open-label NETTER-1 clinical trial evaluating the efficacy and safety of 177Lu-Dotatate in patients with advanced midgut neuroendocrine tumors who have experienced disease progression during first-line treatment with a somatostatin analogue.
Drug-drug interaction between capecitabine and common heartburn medications has a negative effect on progression-free survival and overall survival in patients with GI cancer.
Given the frequency of gene mutations in patients with early-onset CRC, genetic counseling and testing could be considered for this population.
Adding the mesenchymal-epithelial transition (MET) antibody onartuzumab did not significantly improve clinical outcomes.
Survey data from patients receiving care at Boston Medical Center who were navigated for colonoscopy screening illustrates how patients value the services of oncology patient navigators.
A possible association between moderate to heavy alcohol consumption has been shown in previous studies. In this study, investigators examined the relationship between alcohol consumption and colorectal cancer survival remains unclear.
Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
Novel preparation formulation is as effective and safe as current colon prep for colonoscopy. Plus, study participants gave the prep experience a high satisfaction rating.
Because gastric acid suppressants, such as proton pump inhibitors, affect the absorption of some oral cancer medications, researchers sought to determine if proton pump inhibitors impair capecitabine efficacy.
A review of adverse effects and recommended management for 3 kinase inhibitors indicated for the treatment of gastrointestinal cancers.
Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone significantly improved the prevention of CINV in patients with GI and CRC cancers receiving highly or moderately emetogenic chemotherapy.
Applying evolutionary theory improves the accuracy of predicting in which patients Barrett's esophagus will progress to esophageal adenocarcinoma.
Lifestyle and dietary measures for preventing colorectal cancer are extensively studied; however, in this study, researchers looked at a dietary measure that improved survival for patients after diagnosis.
Poor compliance to NCCN guidelines for adjuvant chemotherapy appears to be associated with poorer overall survival.
Research indicates that metformin can confer improved survival for patients with colorectal cancer that also have diabetes.
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
- Distress Management Tool Gets an Update, Patient Version
- PSA Screening Rates Level Off in United States
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|